Fardis Maria

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Director

Х

OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

10% Owner

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

1. Name and Address of Reporting Person\*

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

**IOVANCE BIOTHERAPEUTICS, INC.** 

2. Issuer Name and Ticker or Trading Symbol

IOVA ]

(Last) (First) (Middl	' 3. Da	ate of Earliest Trans	action (I	Month	/Day/Year)	X	below) below)					
999 SKYWAY ROAD, SUITE 150	04/0	03/2017					President and CEO					
(Street) SAN CARLOS CA 9407		Amendment, Date o	f Origina	al File	d (Month/Day/Y	6. Indi Line) X	X Form filed by One Reporting Person					
(City) (State) (Zip)								Form filed by Mo Person	re than One Rep	onung		
Table I -	Non-Derivative	Securities Acc	uired	, Dis	posed of,	or Ben	eficially	Owned				
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (	D) (Instr.	(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		( ,		
Common Stock	04/03/2017		F		51,673 <sup>(1)</sup>	D \$7.15		498,327 <sup>(2)</sup>	D			
Common Stock	06/01/2017		F		143,496(1)	D	\$5.45	354,831(2)	D			
Common Stock	07/01/2017		F		1,994(1)	D	\$7.35	352,837 <sup>(2)</sup>	D			
Common Stock	08/01/2017		F		1,993(1)	D	\$5.7	350,844 <sup>(2)</sup>	D			
Common Stock	09/01/2017		F		1,994(1)	D	\$ <u>6</u>	348,850 <sup>(2)</sup>	D			
Common Stock	10/01/2017		F		1,993 <sup>(1)</sup>	D	\$7.75	346,857 <sup>(2)</sup>	D			
Common Stock	11/01/2017		F		1,994 <sup>(1)</sup>	D	\$7.15	344,863 <sup>(2)</sup>	D			
Common Stock	12/01/2017		F		1,994(1)	D	\$8.8	342,869 <sup>(2)</sup>	D			
Common Stock	01/01/2018		F		1,562 <sup>(1)</sup>	D	\$ <mark>8</mark>	341,307 <sup>(2)</sup>	D			
Common Stock	02/01/2018		F		1,525(1)	D	\$16.5	339,782 <sup>(2)</sup>	D			
Common Stock	03/01/2018		F		1,321(1)	D	\$18.15	338,461(2)	D			
Common Stock	04/01/2018		F		1,321(1)	D	\$16.9	337,140 <sup>(2)</sup>	D			
Common Stock	05/01/2018		F		1,321(1)	D	\$14.6	335,819 <sup>(2)</sup>	D			
Common Stock	06/01/2018		F		1,321(1)	D	\$14.55	334,498 <sup>(2)</sup>	D			
Common Stock	07/01/2018		F		1,321(1)	D	\$12.8	333,177 <sup>(2)</sup>	D			
Common Stock	08/01/2018		F		1,321(1)	D	\$13.7	331,856 <sup>(2)</sup>	D			
Common Stock	09/04/2018		F		1,321(1)	D	\$17.1	330,535 <sup>(2)</sup>	D			
Common Stock	10/01/2018		F		1,321(1)	D	\$11.12	329,214 <sup>(2)</sup>	D			
Common Stock	11/01/2018		F		1,321(1)	D	\$9.62	327,893 <sup>(2)</sup>	D			
Common Stock	12/01/2018		F		1,321(1)	D	\$10.44	326,572 <sup>(2)</sup>	D			
Common Stock	01/02/2019		F		1,562 <sup>(1)</sup>	D	\$9.45	325,010 <sup>(2)</sup>	D			
Common Stock	02/01/2019		F		1,562(1)	D	\$9.26	323,448(2)	D			
Common Stock	03/01/2019		F		1,298(1)	D	\$10.77	322,150 <sup>(2)</sup>	D			
Common Stock	04/01/2019		F		1,321(1)	D	\$9.78	320,829 <sup>(2)</sup>	D			
Common Stock	05/01/2019		F		1,321(1)	D	\$11.14	319,508 <sup>(2)</sup>	D			
Common Stock	06/03/2019		F		1,321(1)	D	\$18.04	318,187 <sup>(2)</sup>	D			
Common Stock	07/01/2019		F		1,321(1)	D	\$24.62	316,866 <sup>(2)</sup>	D			
Common Stock	08/01/2019		F		1,321(1)	D	\$25.17	315,545 <sup>(2)</sup>	D			
Common Stock	09/03/2019		F		1,610(1)	D	\$20.27	313,935 <sup>(2)</sup>	D			
Common Stock	10/01/2019		F		1,894(1)	D	\$18.21	312,041(2)	D			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned     (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Expiration		6. Date Exercisable and Expiration Date (Month/Day/Year)		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.
Shares reported include unvested Restricted Stock Units ("RSUs").

## Remarks:

Pursuant to the SEC Form 4 filing limitation of 30 transactions per form, two Forms 4 are being filed and each shall be deemed to be part of the same Form 4 filing. This is 1 of 2 Forms 4.

<u>/s/ Maria Fardis</u>	<u>12/04/2019</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.